Alberta Investment Management Corp Has $3.09 Million Stake in Moderna, Inc. (NASDAQ:MRNA)

Alberta Investment Management Corp trimmed its stake in Moderna, Inc. (NASDAQ:MRNA) by 6.5% during the fourth quarter, Holdings Channel reports. The fund owned 74,290 shares of the company’s stock after selling 5,196 shares during the quarter. Alberta Investment Management Corp’s holdings in Moderna were worth $3,089,000 as of its most recent filing with the SEC.

A number of other large investors have also recently added to or reduced their stakes in the stock. Blue Trust Inc. lifted its stake in shares of Moderna by 365.6% in the third quarter. Blue Trust Inc. now owns 731 shares of the company’s stock worth $49,000 after buying an additional 574 shares during the last quarter. Wilmington Savings Fund Society FSB raised its holdings in Moderna by 295.0% in the 4th quarter. Wilmington Savings Fund Society FSB now owns 786 shares of the company’s stock worth $33,000 after acquiring an additional 587 shares during the period. Venturi Wealth Management LLC lifted its position in Moderna by 286.2% during the 4th quarter. Venturi Wealth Management LLC now owns 896 shares of the company’s stock worth $37,000 after acquiring an additional 664 shares during the last quarter. Larson Financial Group LLC lifted its position in Moderna by 53.5% during the 3rd quarter. Larson Financial Group LLC now owns 910 shares of the company’s stock worth $61,000 after acquiring an additional 317 shares during the last quarter. Finally, Rakuten Securities Inc. boosted its holdings in Moderna by 477.3% during the third quarter. Rakuten Securities Inc. now owns 941 shares of the company’s stock valued at $63,000 after acquiring an additional 778 shares during the period. Institutional investors own 75.33% of the company’s stock.

Moderna Price Performance

Shares of NASDAQ:MRNA opened at $33.73 on Friday. The business’s fifty day moving average price is $38.17 and its two-hundred day moving average price is $53.20. Moderna, Inc. has a fifty-two week low of $29.25 and a fifty-two week high of $170.47. The stock has a market capitalization of $12.98 billion, a price-to-earnings ratio of -3.63 and a beta of 1.59.

Insider Activity

In other news, insider Shannon Thyme Klinger sold 1,418 shares of the business’s stock in a transaction that occurred on Friday, November 29th. The stock was sold at an average price of $42.79, for a total value of $60,676.22. Following the transaction, the insider now directly owns 19,717 shares of the company’s stock, valued at $843,690.43. The trade was a 6.71 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In the last quarter, insiders have sold 2,664 shares of company stock worth $115,210. Corporate insiders own 15.70% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts have recently commented on MRNA shares. Royal Bank of Canada reiterated a “sector perform” rating and issued a $40.00 price objective on shares of Moderna in a research note on Tuesday. Argus downgraded Moderna from a “buy” rating to a “hold” rating in a research report on Wednesday, December 18th. The Goldman Sachs Group downgraded shares of Moderna from a “buy” rating to a “neutral” rating and lowered their price objective for the stock from $99.00 to $51.00 in a research note on Wednesday, January 29th. Berenberg Bank upped their target price on shares of Moderna from $33.00 to $42.00 and gave the company a “hold” rating in a research note on Thursday, January 16th. Finally, Evercore ISI reduced their price target on shares of Moderna from $60.00 to $50.00 and set an “in-line” rating for the company in a report on Monday, January 27th. Four research analysts have rated the stock with a sell rating, fifteen have given a hold rating, three have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, Moderna has an average rating of “Hold” and an average price target of $60.63.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.